BaylissP F CHarcupJ WMayerMMillionRMurphyJ EPlantBShaoulE. (1974) An open study of two dose levels of ‘Vivalan’ (Viloxazine hydrochloride, ICI 58,834) in depression in general practice. Journal of International Medical Research2, 253.
2.
BaylissP F CDewsburyA RDonaldJ FHarcupJ WMayerMMillionRMollaA LMurphyJ EPlantPShaoulE. (1974) A double-blind controlled trial of ‘Vivalan’ (Viloxazine hydrochloride) and imipramine hydrochloride in the treatment of depression in general practice. Journal of International Medical Research2, 260.
3.
BereenF J (1973) A new potential antidepressive. Lancet1, 379.
4.
BrewerC (1975) A safer antidepressant?British Medical Journal4, 409.
5.
BrionS (1975) Open studies with viloxazine (Vivalan). Journal of International Medical Research3, Suppl. 3, 87.
6.
BrosnanR DBusbyA MHollandR P C (1976) Cases of overdosage with viloxazine hydrochloride (Vivalan). Journal of International Medical Research4, 83.
7.
BrosnanR DHollandR P C (1977) Overdosage attempts with viloxazine (Vivalan). 9th International Congress on Suicide Prevention and Crisis Intervention, Helsinki, June 20th – 23rd 1977.
8.
ElwanOSouiefMHassanM AAllamM. (1976) Psychometric assessment of the therapeutic efficiency of antidepressant agents. Journal of International Medical Research4, 118.
9.
ElwanOTaherYAllamMHassanM A (1976) A comparative study of antidepressants in the treatment of depressive states. Journal of International Medical Research4, 202.
10.
Floru VonLCzarnyGTegelerJ (1976) Doppelblindstudie mit dem neuer antidepressivum viloxazin lm vergleich zu imipramin bei stationänen 50 patientinnen. Arzneimittel Forschung26, 1170.
11.
MallionK BToddA HTurnerR WBainbridgeJ GGreenwoodD TMadinaveitiaJSomervilleA RWhittleB A (1972) 2-(2-Ethoxyphenoxymethyl) tetra-hydro-1, 4-oxazine hydrochloride, a potential psychotropic agent. Nature238, 157.
12.
TsegosI KEkdawiM Y (1974) A double-blind controlled study of viloxazine and imipramine in depression. Current Medical Research Opinion2, 455.
13.
WheatleyD (1974) Viloxazine–a new antidepressant. Current Therapeutic Research16, 821.